Navigation Links
Allos Therapeutics Initiates Study of RH1 in Patients with Advanced Solid Tumors or non-Hodgkin's Lymphoma
Date:11/12/2007

s not to place undue reliance on the forward-looking statements contained in this press release. All forward-looking statements are based on information currently available to the Company on the date hereof, and the Company undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this presentation, except as required by law.

Note: The Allos logo is a trademark of Allos Therapeutics, Inc.


'/>"/>
SOURCE Allos Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
2. Interim Response and Safety Analyses Support Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma
3. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
4. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
5. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
6. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
7. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
8. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
9. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
10. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
11. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2008)...che- , , MONTVALE, N.J., Nov. 19 /PRNewswir...aq: MEMY ) today announced that it has achieved .../MEM 3454, its lead alpha-7 nicotinic receptor ago...zophrenia (CIAS). The Company has randomized 212 ...illion payment from its partner Roche. Memory Pha...
(Date:11/18/2008)...arn more, make a donation or send a Christmas Seal...e-USNewswire/ -- Millions will receive Christmas S...can Lung Association. These decorative holiday sta...ting back to 1907 when the Lung Association led ef...Americans alive today have no vivid memories of ho...
(Date:11/18/2008)...USNewswire/ -- Forty-two leading U. S. scientists ...rum to consider cutting-edge innovations that may ...y from outbreaks of dangerous zoonotic diseases, t...hose innovations: , , , , A "Do...etects highly contagious and dangerous zoonotic di...
(Date:11/18/2008)...iagnosed, elderly AML patients , , PRINCETO...ticals today announced that the first patient has ...y of CPX-351 (Cytarabine:Daunorubicin) Liposome In...loid leukemia (AML). , , The first patient ...ical College of Cornell University and New York P...
Breaking Medicine Technology:Memory Pharmaceuticals Achieves Enrollment Goal for Phase 2 Study of MEM 3454 in Cognitive Impairment Associated With Schizophrenia 2Memory Pharmaceuticals Achieves Enrollment Goal for Phase 2 Study of MEM 3454 in Cognitive Impairment Associated With Schizophrenia 3American Lung Association Celebrates 101st Annual Christmas Seals Campaign 242 Top U.S. Scientists and Specialists Explore Cutting-Edge Innovations to Defend America From Dangerous Zoonotic Diseases 2Celator(R) Pharmaceuticals Announces Enrollment of First Patient in Phase 2 Study with CPX-351 2Celator(R) Pharmaceuticals Announces Enrollment of First Patient in Phase 2 Study with CPX-351 3Dendreon to Hold a Conference Call Today at 9 3A00 AM ET to Provide an Update on Interim Results of Phase 3 PROVENGE IMPACT Trial 3211 1Dendreon to Hold a Conference Call Today at 9 3A00 AM ET to Provide an Update on Interim Results of Phase 3 PROVENGE IMPACT Trial 3211 2Global Sourcing Strategies for the Pharmaceutical Industry 10th 11th November Marriott Princeton New Jersey USA 27033 1Global Sourcing Strategies for the Pharmaceutical Industry 10th 11th November Marriott Princeton New Jersey USA 27033 2Academic Medicine Means Business for Ohio 3A 2437 2 Billion Economic Impact for the State 27032 1Academic Medicine Means Business for Ohio 3A 2437 2 Billion Economic Impact for the State 27032 2Concord Grape Juice Has No Significant Impact on Body Weight 3209 1Concord Grape Juice Has No Significant Impact on Body Weight 3209 2Concord Grape Juice Has No Significant Impact on Body Weight 3209 3
... of market dynamics offers insights into,what will...to,patients, NEW YORK, May 14, 2007 /PRNewswire-US...pment (TB Alliance), a not-for-profit,product dev...d,development of new TB drugs, today released resu...mics of the global TB drug market,that offers a de...
...pitalization and drug withdrawal, CHICAGO, May 15,...migraine patients and physicians commissioned by t...arris Interactive shows that,20 percent of migrain...ive medications that contain barbiturates or opioi... Drug Administration for the,relief of migraines. ...
Other Medicine Technology:New Study Reveals Limitations of a Complex and Challenging Global,Tuberculosis Drug Marketplace 2New Study Reveals Limitations of a Complex and Challenging Global,Tuberculosis Drug Marketplace 3New Study Reveals Limitations of a Complex and Challenging Global,Tuberculosis Drug Marketplace 4Survey: Migraine Patients Taking Potentially Addictive Barbiturate,or Opioid Medications Not Approved by FDA as Migraine Treatments 2Survey: Migraine Patients Taking Potentially Addictive Barbiturate,or Opioid Medications Not Approved by FDA as Migraine Treatments 3Survey: Migraine Patients Taking Potentially Addictive Barbiturate,or Opioid Medications Not Approved by FDA as Migraine Treatments 4Survey: Migraine Patients Taking Potentially Addictive Barbiturate,or Opioid Medications Not Approved by FDA as Migraine Treatments 5Survey: Migraine Patients Taking Potentially Addictive Barbiturate,or Opioid Medications Not Approved by FDA as Migraine Treatments 6
(Date:11/21/2008)...ov. 21, 2008)The University of Texas Health Scienc...ining Excellence in Aging Studies (TEXAS), to prom...restigious $2 million award from the Donald W. Rey...ds., "This will allow us to teach geriatric medic...dical student to practicing physicians. With the r...
(Date:11/21/2008)...Colo., Nov. 21 Heska Cor...l present at the New York Society of,Security Ana...nference on,December 2, 2008 at 1177 Avenue of th...tation is scheduled to begin at 9:35 a.m. Eastern ...ble via live webcast and for two weeks,following ...
(Date:11/21/2008)... Va., Nov. 21 The Gener... following statement today from,GPhA President an...Commission,(FTC) roundtable on "Emerging Health C...e mere fact that the FTC is conducting this roundt...uring that consumers have access to safe and,affo...
(Date:11/21/2008)...wed Banzel proved effective against Lennox-Gastaut... News) -- A new drug called Banzel (rufinamide) ha... severe form of epilepsy called Lennox-Gastaut syn...nced Friday. , The approval was based on result...ients ages 4 to 30. Compared to patients who took ...
Breaking Medicine News(10 mins):Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 2Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 3Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 4Health News:GPhA Statement on FTC Roundtable on Biogenerics 2Health News:FDA Approves New Drug for Severe Epilepsy 2
...umpy old man’, ‘old fogies’ and other such, this i...ersity//. Surprisingly, it’s older people who are ... that people become more positive as they get olde...d to have a "glass empty" view of the world. As ...
...that can keep arteries healthy and prevent heart a...ast one orange// a day could keep cardiac disease ...anones that reduced blood cholesterol levels by 20...on rats, reported the online edition of Daily Mail...
... stress better than those live single, says a stud...r//. Popular perception is that single people have...ws that being in a loving relationship makes it ea...ains of working life, reported online edition of D...
... at Weill Cornell Medical College could prove a po...The compound, called SS31, is able to cross the bl...molecule recently linked to stroke-related tissue ...s, we found that exposing mice to SS31 after an in...
Other Medicine News:Health News:Antioxidant Molecule Could Help Minimize Stroke-Linked Brain Damage 2
Weight: 10.1 kg, Interior Dimensions (WxDxH): 31.1 x 13.6 x 15.3 cm, Exterior Dimensions (WxDxH): 44.6 x 22.4 x 20.5 cm, Capacity: 4 - 50 mL conical tubes, 2 - 300 x 35 mm bottles, 4 - 150 x 35 mm b
...I system consists of four basic components: sample...and metal clamping plate (see diagram). The sample...or producing spots, dots, or slots (see below). Al...hased as an accessory plate in conjunction with a ...
...I system consists of four basic components: sample...and metal clamping plate (see diagram). The sample...or producing spots, dots, or slots (see below). Al...hased as an accessory plate in conjunction with a ...
...I system consists of four basic components: sample...and metal clamping plate (see diagram). The sample...or producing spots, dots, or slots (see below). Al...hased as an accessory plate in conjunction with a ...
Medicine Products: